Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers

Antiviral Research

Volumn 73, Issue 1, 2007, Pages 12-23

  Zhang, Yan Jin ^a,c   Wang, Kai Yu ^a   Stein, David A ^b   Patel, Deendayal ^c   Watkins, Rheba ^a   Moulton, Hong M ^b   Iversen, Patrick L ^b   Matson, David O ^a  

^a CENTER FOR PEDIATRIC RESEARCH   (United States)

^b AVI BIOPHARMA INC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antisense; Antiviral; KSHV; LANA; Morpholino; RTA

Indexed keywords

INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; LATENCY ASSOCIATED NUCLEAR ANTIGEN; MESSENGER RNA; MORPHOLINE DERIVATIVE; OLIGOMER; PEPTIDE DERIVATIVE; SINGLE STRANDED DNA; TRANSACTIVATOR PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; NUCLEOTIDE SEQUENCE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTIGENS, VIRAL; BASE SEQUENCE; CELL LINE, TUMOR; DNA REPLICATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MOLECULAR SEQUENCE DATA; MORPHOLINES; NUCLEAR PROTEINS; TRANS-ACTIVATORS; VIRAL PROTEINS; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 8;

EID: 33846140120     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.017     Document Type: Article

References (66)

1. An F.Q., Compitello N., Horwitz E., Sramkoski M., Knudsen E.S., and Renne R. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J. Biol. Chem. 280 (2005) 3862-3874
2. Aoki Y., Jaffe E.S., Chang Y., Jones K., Teruya-Feldstein J., Moore P.S., and Tosato G. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93 (1999) 4034-4043
3. Ballestas M.E., Chatis P.A., and Kaye K.M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284 (1999) 641-644
4. Beelman C.A., and Parker R. Degradation of mRNA in eukaryotes. Cell 81 (1995) 179-183
5. Cesarman E., Chang Y., Moore P.S., Said J.W., and Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332 (1995) 1186-1191
6. Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M., and Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86 (1995) 2708-2714
7. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., and Moore P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266 (1994) 1865-1869
8. Corey D.R., and Abrams J.M. Morpholino antisense oligonucleotides: tools for investigating vertebrate development. Genome Biol. 2 (2001) 1-3
9. Curreli F., Cerimele F., Muralidhar S., Rosenthal L.J., Cesarman E., Friedman-Kien A.E., and Flore O. Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. J. Virol. 76 (2002) 5208-5219
10. Deas T.S., Binduga-Gajewska I., Tilgner M., Ren P., Stein D.A., Moulton H.M., Iversen P.L., Kauffman E.B., Kramer L.D., and Shi P.Y. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79 (2005) 4599-4609
11. Dittmer D., Lagunoff M., Renne R., Staskus K., Haase A., and Ganem D. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 72 (1998) 8309-8315
12. Ensoli B., Barillari G., Buonaguro L., and Gallo R.C. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv. Exp. Med. Biol. 303 (1991) 27-38
13. Fakhari F.D., and Dittmer D.P. Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 76 (2002) 6213-6223
14. Friborg Jr. J., Kong W., Hottiger M.O., and Nabel G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402 (1999) 889-894
15. Gao S.J., Boshoff C., Jayachandra S., Weiss R.A., Chang Y., and Moore P.S. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 15 (1997) 1979-1985
16. Gao S.J., Kingsley L., Hoover D.R., Spira T.J., Rinaldo C.R., Saah A., Phair J., Detels R., Parry P., Chang Y., and Moore P.S. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N. Engl. J. Med. 335 (1996) 233-241
17. Ghosh C., and Iversen P.L. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev. 10 (2000) 263-274
18. Hudziak R.M., Summerton J., Weller D.D., and Iversen P.L. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. 10 (2000) 163-176
19. Jones K.D., Aoki Y., Chang Y., Moore P.S., Yarchoan R., and Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94 (1999) 2871-2879
20. Kedes D.H., and Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Invest. 99 (1997) 2082-2086
21. Kinney R.M., Huang C.Y., Rose B.C., Kroeker A.D., Dreher T.W., Iversen P.L., and Stein D.A. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J. Virol. 79 (2005) 5116-5128
22. Lan K., Kuppers D.A., Verma S.C., and Robertson E.S. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J. Virol. 78 (2004) 6585-6594
23. Liebhaber S.A. mRNA stability and the control of gene expression. Nucleic Acids Symp. Ser. 36, (1997) 29-32
24. Lim C., Choi C., and Choe J. Mitotic chromosome-binding activity of latency-associated nuclear antigen 1 is required for DNA replication from terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus. J. Virol. 78 (2004) 7248-7256
25. Lim C., Sohn H., Lee D., Gwack Y., and Choe J. Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. J. Virol. 76 (2002) 10320-10331
26. Lukac D.M., Kirshner J.R., and Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J. Virol. 73 (1999) 9348-9361
27. Lukac D.M., Renne R., Kirshner J.R., and Ganem D. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252 (1998) 304-312
28. McCaffrey A.P., Meuse L., Karimi M., Contag C.H., and Kay M.A. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38 (2003) 503-508
29. Medveczky M.M., Horvath E., Lund T., and Medveczky P.G. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11 (1997) 1327-1332
30. Menezes J., Leibold W., Klein G., and Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22 (1975) 276-284
31. Miller G., Heston L., Grogan E., Gradoville L., Rigsby M., Sun R., Shedd D., Kushnaryov V.M., Grossberg S., and Chang Y. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J. Virol. 71 (1997) 314-324
32. Moore P.S., Boshoff C., Weiss R.A., and Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274 (1996) 1739-1744
33. Morcos P.A. Achieving efficient delivery of morpholino oligos in cultured cells. Genesis 30 (2001) 94-102
34. Moulton H.M., Hase M.C., Smith K.M., and Iversen P.L. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13 (2003) 31-43
35. Moulton H.M., Nelson M.H., Hatlevig S.A., Reddy M.T., and Iversen P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15 (2004) 290-299
36. Nasevicius A., and Ekker S.C. Effective targeted gene 'knockdown' in zebrafish. Nat. Genet. 26 (2000) 216-220
37. Nelson M.H., Stein D.A., Kroeker A.D., Hatlevig S.A., Iversen P.L., and Moulton H.M. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug. Chem. 16 (2005) 959-966
38. Neuman B.W., Stein D.A., Kroeker A.D., Churchill M.J., Kim A.M., Kuhn P., Dawson P., Moulton H.M., Bestwick R.K., Iversen P.L., and Buchmeier M.J. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79 (2005) 9665-9676
39. Neuman B.W., Stein D.A., Kroeker A.D., Paulino A.D., Moulton H.M., Iversen P.L., and Buchmeier M.J. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78 (2004) 5891-5899
40. Penberthy W.T., Shafizadeh E., and Lin S. The zebrafish as a model for human disease. Front. Biosci. 7 (2002) d1439-d1453
41. Radkov S.A., Kellam P., and Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6 (2000) 1121-1127
42. Rainbow L., Platt G.M., Simpson G.R., Sarid R., Gao S.J., Stoiber H., Herrington C.S., Moore P.S., and Schulz T.F. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 71 (1997) 5915-5921
43. Renne R., Barry C., Dittmer D., Compitello N., Brown P.O., and Ganem D. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J. Virol. 75 (2001) 458-468
44. Renne R., Zhong W., Herndier B., McGrath M., Abbey N., Kedes D., and Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2 (1996) 342-346
45. Russo J.J., Bohenzky R.A., Chien M.C., Chen J., Yan M., Maddalena D., Parry J.P., Peruzzi D., Edelman I.S., Chang Y., and Moore P.S. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad Sci. U.S.A. 93 (1996) 14862-14867
46. Sarid R., Flore O., Bohenzky R.A., Chang Y., and Moore P.S. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J. Virol. 72 (1998) 1005-1012
47. Schmajuk G., Sierakowska H., and Kole R. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J. Biol. Chem. 274 (1999) 21783-21789
48. Scholpp S., and Brand M. Morpholino-induced knockdown of zebrafish engrailed genes eng2 and eng3 reveals redundant and unique functions in midbrain-hindbrain boundary development. Genesis 30 (2001) 129-133
49. Sergerie Y., and Boivin G. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J. Clin. Microbiol. 41 (2003) 3897-3900
50. Shinohara H., Fukushi M., Higuchi M., Oie M., Hoshi O., Ushiki T., Hayashi J., and Fujii M. Chromosome binding site of latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus is essential for persistent episome maintenance and is functionally replaced by histone H1. J. Virol. 76 (2002) 12917-12924
51. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., d'Agay M.F., Clauvel J.P., Raphael M., Degos L., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 (1995) 1276-1280
52. Staskus K.A., Sun R., Miller G., Racz P., Jaslowski A., Metroka C., Brett-Smith H., and Haase A.T. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J. Virol. 73 (1999) 4181-4187
53. Stein D.A., Skilling D.E., Iversen P.L., and Smith A.W. Inhibition of vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11 (2001) 317-325
54. Strum R.D., and Kirk D.E. First Principles of Discrete Systems and Digital Signal Processing (1988), Addison-Wesley Publishing Company Reading, MA
55. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489 (1999) 141-158
56. Summerton J., and Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7 (1997) 187-195
57. Sun R., Lin S.F., Gradoville L., Yuan Y., Zhu F., and Miller G. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl. Acad Sci. U.S.A. 95 (1998) 10866-10871
58. Sun R., Lin S.F., Staskus K., Gradoville L., Grogan E., Haase A., and Miller G. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 73 (1999) 2232-2242
59. Talbot S.J., Weiss R.A., Kellam P., and Boshoff C. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology 257 (1999) 84-94
60. van den Born E., Stein D.A., Iversen P.L., and Snijder E.J. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. J. Gen. Virol. 86 (2005) 3081-3090
61. Verma S.C., Borah S., and Robertson E.S. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 78 (2004) 10348-10359
62. Wang S.E., Wu F.Y., Fujimuro M., Zong J., Hayward S.D., and Hayward G.S. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP. J. Virol. 77 (2003) 600-623
63. Ye F.C., Zhou F.C., Yoo S.M., Xie J.P., Browning P.J., and Gao S.J. Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J. Virol. 78 (2004) 11121-11129
64. Zhu J., Trang P., Kim K., Zhou T., Deng H., and Liu F. Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc. Natl. Acad Sci. U.S.A. 101 (2004) 9073-9078
65. Zimring J.C., Goodbourn S., and Offermann M.K. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J. Virol. 72 (1998) 701-707
66. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415